Provention Bio Reports Second Quarter 2019 Financial Results

~ PRV-031 Granted Breakthrough Therapy Designation for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals ~ Results from "At-Risk" Study Published in The New England Journal of Medicine and Presented at ADA; Single Course of PRV-031 Delayed Onset of Type 1 Diabetes by at Least Two Years

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here